State of the Art and Future Prospects of the Treatment of Acute Myeloid Leukemia
Major clinical trials published during the 1980s failed to demonstrate a substantial therapeutic progress in chemotherapy for patients with AML. In particular, it remained unanswered whether more chemotherapy — in terms of its intensity as well as duration — produces more cures. Bone marrow transplantation has not been adequately compared to chemotherapy on the basis of comparable groups. Chemotherapy may be modulated by hemopoietic growth factors in both its myelotoxicity and its antileukemic activity as from first clinical results. We discuss here major results from the above therapeutic approaches and their role in AML management.
KeywordsCytosine Arabinoside Remission Duration Bone Marrow Blast Relapse Free Survival Acute Nonlymphocytic Leukemia
Unable to display preview. Download preview PDF.
- 2.Bücher T, Hiddemann W, Koenigsmann Met al (1991) Recominant human granulocyte-macrophage colony-stimulating factor following chemotherapy in patients with acute mayloid leukemia at higher age or after relapse. Blood 78: 1190–1197Google Scholar
- 3.Büchner T, Hiddemann W, Löffler H et al (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute mayloid leukemia (AML): data from AMLCG. Semin Hematol 28, Suppl 4: 76–79Google Scholar
- 8.Kurrle E, Ehninger G, Fackler-Schwalbe E et al (1990) Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia. In Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias II. Springer, Berlin Heidelberg New York, pp 209–215 ( Hämatologie and Bluttransfusion, Vol 33 )Google Scholar
- 12.Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ (1986) Principal results of the Medical Research Council’s 8th Acute Myeloid Leukemia Trial. Lancet ii: 1236–1241Google Scholar
- 13.Sauter C, Fopp M, Imbach P et al. (1984) Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet ii 379–382Google Scholar